Artificial Intelligence
Persistent Epithelial Defect (PED) – Market Insights, Epidemiology, and Market Forecast – 2030
New York, Aug. 26, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Persistent Epithelial Defect (PED) – Market Insights, Epidemiology, and Market Forecast – 2030” – https://www.reportlinker.com/p05921875/?utm_source=GNW
The Persistent Epithelial Defect (PED) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted PED symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Persistent Epithelial Defect (PED) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Persistent Epithelial Defect (PED) Disease Understanding and Treatment Algorithm
Persistent Epithelial Defect (PED) Overview
Persistent Epithelial Disease, also known as persistent corneal epithelial defects (PEDs or PCEDs), results from the failure of rapid re-epithelialization and closure within 10–14 days after a corneal injury, even with standard supportive treatment. PED is defined as “defects persisting for more than 2 weeks without improvement despite conventional treatment, such as non-preservative artificial tears or extended wear soft contact lenses”. PEDs commonly extend into the stromal layer, causing stromal melting, secondary ulceration, and stromal scarring. Also, an insult to the cornea resulting in an acute epithelial defect is a lesion that usually heals over the 7–14 days time frame. In contrast, a persistent epithelial defect is unable to close within this normal interval.
The normal corneal wound healing process can be disrupted from defective epithelial adhesion, limbal stem cell deficiency, surface trauma, medications, infections, and several other etiologies. Such defects are especially common in individuals with metaherpes, neurotrophic keratopathy, or diabetic keratopathy.
Some of the symptoms of PEDs are loss of corneal epithelial cells, delayed epithelialization post-injury, nonhealing epithelial defect and others which can be commonly due to Epithelial/limbal, inflammatory disease, Neurotrophic, mechanical causes, and others. Evaluating a PED involves instillation of fluorescein to monitor the size, location, and depth of the defect. A thorough physical exam should reveal findings such as inflammation in the anterior chamber, eyelid abnormalities, or decreased sensation of the cornea.
Although several therapies exist and an increasing number of novel approaches are emerging, treatment of PEDs can still be quite challenging. It is important to treat the underlying causative condition, which may include infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. Furthermore, standard treatments, such as bandage contact lenses (BCLs) and artificial tears (ATs), aim to provide barrier protection to the epithelial layers.
Persistent Epithelial Defect (PED) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Persistent Epithelial Defect (PED) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Persistent Epithelial Defect (PED) market report gives a thorough understanding of PED symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides PED symptoms of treatment algorithms and treatment guidelines for PED symptoms in the US, Europe, and Japan.
<>Persistent Epithelial Defect (PED) Epidemiology
The Persistent Epithelial Defect symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Defect (PED) epidemiology segmented as the Total Incident cases of Persistent epithelial defect, Etiology-specific cases of Persistent Epithelial Defect (PED). The report includes the Incident scenario of PED symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
<>Country Wise- Persistent Epithelial Defect (PED) Epidemiology
The epidemiology segment also provides the Persistent Epithelial Defect (PED) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total Incident population of Persistent Epithelial Defect (PED) in 7MM countries was estimated to be 238,058 cases in 2017.
Persistent Epithelial Defect (PED) Drug Chapters
The drug chapter segment of the Persistent Epithelial Defect (PED) report encloses the detailed analysis of PED marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Persistent Epithelial Defect (PED) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The therapeutic market size of PED in the US is mainly accounted for treatment options, such as approved therapy i.e Oxervate and off-label therapies such as lubricants, punctal occlusion, bandage contact lens, topical antibiotics, steroids and others. Amniotic membrane grafting, autologous serum, scleral contact lenses, have been recommended for the treatment of refractory cases.
Products detail in the report…
Persistent Epithelial Defect (PED) Emerging Drugs
Nexagon: OcuNexus Therapeutics, Eyevance Pharmaceuticals
It a first-in-class natural, antisense therapy that downregulates the cell membrane hemichannel forming protein, connexin43 (Cx43). Targeting the gap junctions may prevent immune system responses that may lead to inflammatory cascade and promote the microvasculature and regeneration of corneal epithelium. Nexagon has a market advantage in the US, as it received orphan drug designation from the FDA. It is being developed by OcuNexus Therapeutics in partnership with Eyevance Pharmaceuticals. Currently, the drug is under phase II studies for PED.
Products detail in the report…
Persistent Epithelial Defect (PED) Market Outlook
The Persistent Epithelial Defect (PED) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Persistent Epithelial Defect (PED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Persistent Epithelial Defect (PED) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to the report, Persistent Epithelial Defect (PED) market in 7MM is expected to change in the study period 2017–2030.
The first step in the management of any epithelial abnormality is to determine the etiology of the disease. Currently, “bandage” methods are used to help re-epithelialize a cornea. The current approaches include Aggressive lubrication, Punctal occlusion, Bandage soft contact lens, Pressure patching, Tetracyclines, prophylactic topical antibiotics and steroids. For the treatment of refractory cases, Amniotic membrane grafting, autologous serum, Scleral contact lenses, and others have recommended. In severe cases, a conjunctival graft may be placed over the cornea.
Key Findings
This section includes a glimpse of the Persistent Epithelial Defect (PED) market in 7MM. The market size of PED in the seven major markets was found to be USD 179.1 million in 2017.
The United States Market Outlook
This section provides the total Persistent Epithelial Defect (PED) market size and market size by therapies in the United States.
The United States accounts for the highest market size of PED in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Aggressive lubrication is typically the first-line therapy with either high-frequency application of preservative-free artificial tears or sterile ophthalmic ointment. This may prove to be particularly difficult with the noncompliant patient. Punctal occlusion may increase epithelial contact time with lubricating tears and ointments, and patients may benefit from temporary or permanent occlusion of the punctual. However, this is not recommended in the circumstances requiring the continued use of toxic agents.
If the response to the previous measures is inadequate or for refractory cases, therapies such as Amniotic membrane grafting, autologous serum are the choice. Autologous serum drops have been reported to be beneficial in the treatment of persistent epithelial defect recalcitrant to conventional therapy.
Along with this, Oxervate – first-ever recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis recently, which is one of the underlying etiologies for PED, thus may help some of the PED patients. Also, Dompé Farmaceutici may have the chance to expand its indication to PED with observed results in the future. It is the first-ever topical biologic medication approved in ophthalmology and has given a boost to a similar type of researches.
EU-5 Countries: Market Outlook
The total Persistent Epithelial Defect (PED) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
if the etiology of the PED is due to the deficiency of the stem cells that are responsible for repopulating the epithelium, then Limbal stem cell transplantation (surgical replacement with stem cell (allo or autografts) is indicated. This is frequently seen in conditions such as ocular cicatricial pemphigoid, Stevens–Johnson syndrome, and severe alkali burns and others. Moreover, Scleral contact lenses, including the prosthetic replacement of the ocular surface ecosystem (PROSE) lens, may be utilized for refractory persistent epithelial defects.
One recent treatment alternative is the topical use of Regenerating Agent Eye Drops (RGTAs). RGTA (OTR4120 (Cacicol20); laboratories Théa,) is a carboxymethyl dextran sulfate polymer bioengineered to replace heparan sulfate, which is an important factor both for matrix proteins and for growth factors. It is available in Europe as a novel therapeutic approach to treat PED patients, that are resistant to conventional therapy.
Japan Market Outlook
The total Persistent Epithelial Defect (PED) market size and market size by therapies in Japan are also mentioned.
Persistent Epithelial Defect (PED) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Persistent Epithelial Defect (PED) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Persistent Epithelial Defect (PED) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Persistent Epithelial Defect (PED) key players involved in developing targeted therapeutics.
Major players include OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneX Biotherapeutics, Recordati Rare Diseases., Mimetech. Nexagon (OcuNexus Therapeutics, Eyevance Pharmaceuticals) is expected to get launched in the US market by 2022.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Persistent Epithelial Defect (PED) emerging therapies.
Reimbursement Scenario in Persistent Epithelial Defect (PED)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.
Payers have established their therapeutic guidelines, manage access more tightly and scrutinize the price of new therapies, meaning pharma companies need to provide the evidence sought by payers, specifical information such as comparative effectiveness, cost-effectiveness and real-world data. Gaining market access in pharma across Europe has always presented challenges to pharmaceutical firms. The region has a common regulator, the European Medicines Agency, and most of its citizens receive healthcare from government-funded, often country-wide, health systems.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Persistent Epithelial Defect (PED) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Persistent Epithelial Defect (PED) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Persistent Epithelial Defect (PED) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
• The report covers the descriptive overview of Persistent Epithelial Defect (PED), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
• Comprehensive insight has been provided into the Persistent Epithelial Defect (PED) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Persistent Epithelial Defect (PED) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Persistent Epithelial Defect (PED) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Persistent Epithelial Defect (PED) market
Report Highlights
• In the coming years, Persistent Epithelial Defect (PED) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Persistent Epithelial Defect (PED) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for PED. Launch of emerging therapies will significantly impact the Persistent Epithelial Defect (PED) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for PED.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Persistent Epithelial Defect (PED) Report Insights
• Patient Population
• Therapeutic Approaches
• Persistent Epithelial Defect (PED) Pipeline Analysis
• Persistent Epithelial Defect (PED) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Persistent Epithelial Defect (PED) Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
<>• Persistent Epithelial Defect (PED) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Persistent Epithelial Defect (PED) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Questions
Market Insights:
• What were the Persistent Epithelial Defect (PED) Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Persistent Epithelial Defect (PED) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Persistent Epithelial Defect (PED)market Size during the forecast period (2017–2030)?
• At what CAGR, the Persistent Epithelial Defect (PED) market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the Persistent Epithelial Defect (PED) market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Persistent Epithelial Defect (PED) market growth till 2030 and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
• What is the disease risk, burden and unmet needs of the Persistent Epithelial Defect (PED)?
• What is the historical Persistent Epithelial Defect (PED) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
• What would be the forecasted patient pool of Persistent Epithelial Defect (PED) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Persistent Epithelial Defect (PED)?
• Out of all 7MM countries, which country would have the highest Incident population of Persistent Epithelial Defect (PED) during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Persistent Epithelial Defect (PED)?
• What are the current treatment guidelines for the treatment of Persistent Epithelial Defect (PED) in the USA, Europe, and Japan?
• What are the Persistent Epithelial Defect (PED) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Persistent Epithelial Defect (PED)?
• How many therapies are developed by each company for the treatment of Persistent Epithelial Defect (PED)?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Persistent Epithelial Defect (PED)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Persistent Epithelial Defect (PED) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Persistent Epithelial Defect (PED) and their status?
• What are the key designations that have been granted for the emerging therapies for Persistent Epithelial Defect (PED)?
• What are the global historical and forecasted market of Persistent Epithelial Defect (PED)?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Persistent Epithelial Defect (PED) market
• To understand the future market competition in the Persistent Epithelial Defect (PED) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Persistent Epithelial Defect (PED) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Persistent Epithelial Defect (PED) market
• To understand the future market competition in the Persistent Epithelial Defect (PED) market
Read the full report: https://www.reportlinker.com/p05921875/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Artificial Intelligence
US Air Force Awards ThroughPut.ai Direct-to-Phase-II Contract for Boeing, Lockheed Martin, and Sikorsky Mission Design Series to Accelerate Aircraft Readiness
Leveraging Data to Drive Maintenance-first actions that improve overall supply chain throughput across the DAF.
NEW YORK, May 28, 2024 /PRNewswire/ — ThroughPut.ai, the Supply Chain Decision Intelligence Pioneer, announces it has been selected by AFWERX for a (SBIR Direct-to-Phase II contract) in the amount of $1,248,627.00 focused on “AI-Powered Proactive Supply Chain Capabilities” to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and now on April 17th, 2024, ThroughPut.ai will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.
“ThroughPut.ai looks forward to supporting efforts to accelerate inventory flow across the United States Air Force,” said Ali Raza, CEO & Founder of ThroughPut.ai. “By driving inventory/materiel management changes at the maintenance endpoint first, supply chain improvements can then be amplified across the greater industrial base to create aircraft capacity.”
“The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.”
About (ThroughPut.ai)
ThroughPut.ai is a Silicon Valley-based supply chain optimization & predictive replenishment company. The company’s software AI platform has the ability to identify location-, product-, and customer-based demand changes sooner in order to adjust order frequencies, vendor sources, and parts buffer levels at a global and local scale. ThroughPut’s platform was designed by Fortune 500 & technology executives with real-world experience managing demand & supply chain disruptions and war-zone logistics across the Middle East.
About AFRLThe Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space and cyberspace force. With a workforce of more than 12,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit afresearchlab.com.
About AFWERXAs the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at five hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has executed over 6,100 new contracts worth more than $4 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: www.afwerx.com.
Company Press Contact:Ali RazaCEO/[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/us-air-force-awards-throughputai-direct-to-phase-ii-contract-for-boeing-lockheed-martin-and-sikorsky-mission-design-series-to-accelerate-aircraft-readiness-302156930.html
Artificial Intelligence
Data Center Investments Soar: 200% Rise Since 2016 and Projected 89% Increase by 2028
USA News Group CommentaryIssued on behalf of Avant Technologies Inc.
VANCOUVER, BC, May 28, 2024 /PRNewswire/ — Since 2016, investment in data centre infrastructure has risen 200%, with a further 89% increase expected by 2028 as more opportunities emerge with the rise of artificial intelligence (AI). According to Jones Lang LaSalle Inc.’s CEO Christian Ulbrich, data centers are “the hottest asset class at the moment.” Analysts at Technavio are projecting the global data center market to record an additional US$329.82 billion in growth at a CAGR of 12.73% through 2027. Capitalizing on the opportunity are several players recently announcing developments regarding their involvement in the data centers sector, including
Avant Technologies Inc. (OTCQB: AVAI), Amazon.com, Inc. (NASDAQ: AMZN), Applied Digital Corporation (NASDAQ: APLD), Digital Realty Trust, Inc. (NYSE: DLR), and Equinix, Inc. (NASDAQ: EQIX).
As an early pioneer in generative AI, Avant Technologies Inc. (OTCQB: AVAI) continues to enhance its flagship asset, Avant AITM, a sophisticated machine and deep learning AI system designed for versatility and customization across various industries and applications. Recently, Avant announced plans to equip its AI-managed data center, currently in development, with High-Performance Computing (HPC) systems. According to IBM, HPC technology utilizes clusters of powerful processors working in parallel to process massive multi-dimensional data sets and solve complex problems at exceptionally high speeds.
“The rise of AI is revolutionizing industries, and Avant Technologies is committed to being at the forefront of this transformation,” said William Hisey, CEO of Avant. “By building an AI-managed data center with HPC systems, we will gain the computational power and infrastructure required to train and deploy sophisticated AI models, which will ultimately provide even greater value to our customers.”
The new data center will leverage AI-driven management technology to optimize resource allocation and enhance efficiency in all aspects of data center operations. Avant will meticulously design its HPC infrastructure to meet the demands of AI workloads, selecting high-performance CPUs and GPUs (or TPUs) specifically suited for deep learning tasks. This cutting-edge facility will enable Avant to accelerate AI advancements, delivering innovative solutions to clients by improving data center efficiency and empowering them with exceptional AI capabilities.
Additionally, Avant will implement a high-speed network to ensure efficient data transfer and select a scalable storage solution to manage the large datasets necessary for training and utilizing AI models. The HPC systems will prioritize security, incorporating robust measures to protect sensitive data and create a secure environment for AI deployment. Furthermore, the data center will integrate energy-efficient technologies and sustainable design practices, reflecting Avant’s commitment to environmental responsibility.
Avant Technologies also recently announced plans to implement AI-empowered Zero Trust Architecture (ZTA) across its data center operations. Additionally, the company has expanded its AvantAI™ platform to include intelligent, proactive monitoring and management for data centers.
Over the past few weeks Amazon.com, Inc. (NASDAQ: AMZN) has collectively committed to investing $20 billion into new data centers for its subsidiary Amazon Web Services (AWS). The first to be announced was an $11-billion data center to be built in Indiana, with another $9 billion set to accelerate cloud-infrastructure in Singapore. The moves fall in line with Amazon CEO Andy Jassy’s projection that 85% of IT spending will remain on premises, in the race for Gen AI supremacy.
Amazon also recently announced an extension on its partnership between AWS and CrowdStrike to unify cybersecurity protection on its CrowdStrike Falcon platform. As per the agreement, Amazon is replacing a variety of cloud point products with Falcon Cloud Security, is using Falcon Next-Gen SIEM to secure big data logging and is deploying Identity Threat Detection and Response to prevent identity-based attacks.
“CrowdStrike and AWS have a deep history of working together to secure the most innovative companies in the world,” said CJ Moses, Chief Information Security Officer and Vice President of Security Engineering at Amazon. “Amazon uses CrowdStrike to provide visibility, detection, and response across our businesses in order to protect the cloud, infrastructure, and services for our customers. This is part of our shared mission to help all organizations build, operate, and secure their business.”
In a move to shore-up its market position as a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (“HPC”) applications, Applied Digital Corporation (NASDAQ: APLD) recently announced the appointment of industry veteran Todd Gale as its new Chief Development Officer. The announcement came just one month after the company announced it had issued a $50 million unsecured convertible debenture to advance its HPC Data Center Project in Ellendale, North Dakota.
“We intend to use the net proceeds from the private financing, supplemented by the proceeds from our announced sale of the Garden City facility, to finance substantial advancements in our construction phase of the HPC data center in Ellendale, North Dakota,” said David Rench, CFO of Applied Digital. “Concurrently, we continue negotiating our project-level financing to ensure timely project completion and fulfillment of our contractual obligations.”
Applied Digital intends to utilize chipmaking giant NVIDIA’s new Blackwell platform into its cloud offerings. The company’s next-generation data center campuses are specifically designed to host HPC/AI applications, offering more cost-effective and efficient alternatives to traditional data centers.
In Japan, Digital Realty Trust, Inc. (NYSE: DLR) recently announced the expansion of its NRT Campus, by commencing construction of its third data center to support AI. Upon completion of the site in late 2025, the campus’s capacity will rise to 104MW, with the intention of meeting rising demand for next-generation infrastructure, and seamless access to Japan’s connected data communities.
“Japan’s rapidly increasing demand for AI deployments creates the need for scalable, flexible, and highly connected AI-ready data centers in the Tokyo metropolitan area,” said Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty. “We believe NRT14’s next-generation data center infrastructure and Digital Realty’s connected global open data center platform provide the foundational pillars our customers need to drive innovation in the coming years.”
Equinix, Inc. (NASDAQ: EQIX), another digital infrastructure company, has recently launched a $600 million joint venture with PGIM Real Estate to develop and operate the first xScale data center in the US, situated in California’s Silicon Valley. This follows their successful collaboration on the first xScale data center in Australia in 2022, which was part of a similar $575 million joint venture announced in 2021.
Under the terms of the new agreement, PGIM Real Estate will hold an 80% equity interest in the joint venture, while Equinix will retain a 20% equity stake. xScale data centers by Equinix enable hyperscale companies to expand their core deployments within Equinix’s IBX data centers, facilitating growth in over 70 global metros through a platform that supports direct interconnections with more than 10,000 customers.
This joint venture complements Equinix’s existing hyperscale collaborations in Europe, Asia-Pacific, and the Americas, significantly enhancing the global xScale data center portfolio. Once completed, this global expansion is set to exceed $8 billion, encompassing more than 35 facilities and providing over 725 megawatts of power capacity.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.co.uk/news-releases/data-center-investments-soar-200-rise-since-2016-and-projected-89-increase-by-2028-302156928.html
Artificial Intelligence
Lucinity Wins the Microsoft Partner Awards for 2024 for Partner of the Year – Iceland and Sustainability and Social Impact
REYKJAVÍK, Iceland, May 28, 2024 /PRNewswire/ — Lucinity, a leading AI company for financial crime prevention, won two awards at the Microsoft Partner Awards for 2024, including Partner of the Year – Iceland and Sustainability and Social Impact, highlighting Lucinity’s innovations and contribution to positive societal change.
“Congratulations to Lucinity for being recognized as the Partner of the Year – Iceland 2024! Lucinity is leading digital transformation and delivering innovative products in their domain,” says Microsoft’s leadership.
“For the past year, they have played a key role with their offerings, skilled resources, and their ability to drive change and innovative solutions both locally in Iceland and across the globe. Lucinity has had significant social impact and growth while supporting our joint customers in their AI-transformation journeys.”
In June 2023, Lucinity launched the world’s first copilot for FinCrime prevention powered by Microsoft Azure OpenAI called Luci. Luci stands out in the financial services industry with specialized skills for FinCrime prevention such as adverse media checks, case analysis, and SAR writing.
Built on the robust and scalable Microsoft Azure platform, Lucinity offers customers a trusted SaaS product. Additionally, Lucinity’s presence on the Microsoft Azure Marketplace allows companies to leverage their Microsoft Azure credits to access the platform.
The seamless integration with Microsoft’s Azure stack has enabled Lucinity to implement advanced AI capabilities, fostering rapid innovation and enabling banks and fintech companies to utilize AI securely and audibly. Furthermore, Luci significantly reduces investigation times from 2.5 hours to just 25 minutes, saving Tier 1 banks an estimated $25 million annually.
Guðmundur Kristjánsson (GK), Lucinity’s Founder and CEO comments, “These awards are a testament to the strength and reliability of our solutions, made possible by our strategic partnership with Microsoft. Utilizing Microsoft Azure, we have been able to drive rapid innovation and create a robust, scalable platform that meets the rigorous requirements of compliance teams.”
On the Sustainability and Social Impact Partner Award, Microsoft says, “Lucinity, with their innovative AI solutions, has really tried to combat this huge global challenge. They use ‘Human AI’ to enhance financial crime prevention, combining AI with human expertise for efficient, user-friendly solutions. Additionally, Lucinity has developed a tool called Luci, an AI-powered copilot that helps transform financial crime prevention from a process that took hours to one that takes minutes.”
Logo: https://mma.prnewswire.com/media/2208676/4669079/Lucinity_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lucinity-wins-the-microsoft-partner-awards-for-2024-for-partner-of-the-year—iceland-and-sustainability-and-social-impact-302156888.html
-
Artificial Intelligence4 days ago
Titans of Tech: GP Bullhound releases its annual report on the European tech ecosystem
-
Artificial Intelligence4 days ago
Bybit Web3 Announces Upcoming IDO for Aperture Finance, Simplifying Web3 Finance
-
Uncategorized4 days ago
GienTech Hosted the “2024 GienTech Digital Transformation Conference” to Promote Overseas Collaborative Ecosystem Development
-
Uncategorized4 days ago
Hyreo ushers in a New Dawn for Recruitment Technology with Hyreo Labs
-
Artificial Intelligence6 days ago
HONOR Unveils Four-Layer AI Architecture and Forges Ahead with Google Cloud for More AI Experiences at VivaTech 2024
-
Artificial Intelligence4 days ago
Overseas Expansion Strategy of K-OTT Introduced in France, KOCCA holds the ‘2024 Korea-France Content Forum’
-
Artificial Intelligence4 days ago
IoT Node and Gateway Market worth $604.7 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence4 days ago
Northern Data Group’s Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas